EcoDrugPlus

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSBGRG00000018085
Gene Symbol: CHRNA4
1 Cross references
206 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 7 Subunit

Ensembl ID : ENSBGRG00000016143
Gene Symbol: CHRNA7
1 Cross references
249 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSBGRG00000008531
Gene Symbol: CHRNB2
1 Cross references
198 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSBGRG00000019896
Gene Symbol: CHRNB4
1 Cross references
199 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSBGRG00000007892
Gene Symbol: F2R
1 Cross references
330 Possible Orthologues:

Coagulation Factor Ii, Thrombin

Ensembl ID : ENSBGRG00000013793
Gene Symbol: F2
1 Cross references
86 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSBGRG00000000221
Gene Symbol: F3
1 Cross references
246 Possible Orthologues:

Coagulation Factor Vii

Ensembl ID : ENSBGRG00000015550
Gene Symbol: F7
1 Cross references
203 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSBGRG00000015612
Gene Symbol: F10
1 Cross references
239 Possible Orthologues:

Coagulation Factor Xi

Ensembl ID : ENSBGRG00000016074
Gene Symbol: F11
1 Cross references
215 Possible Orthologues:

Coagulation Factor Xii

Ensembl ID : ENSBGRG00000017736
Gene Symbol: F12
1 Cross references
187 Possible Orthologues:

Coiled-Coil Domain Containing 6

Ensembl ID : ENSBGRG00000025238
Gene Symbol: CCDC6
1 Cross references
223 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).